tiprankstipranks
Trending News
More News >
Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H (HK:2315)
:2315
Hong Kong Market
Advertisement

Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H (2315) AI Stock Analysis

Compare
1 Followers

Top Page

HK:2315

Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H

(2315)

Rating:66Neutral
Price Target:
HK$27.00
▲(9.85% Upside)
The stock's overall score is driven primarily by its strong financial performance and impressive technical momentum. However, a very high P/E ratio indicates potential overvaluation, which is a significant risk factor. The lack of earnings call and corporate event data limits further insights.

Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H (2315) vs. iShares MSCI Hong Kong ETF (EWH)

Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H Business Overview & Revenue Model

Company DescriptionBiocytogen Pharmaceuticals (Beijing) Co., Ltd., a biotechnology company, engages in the research and development of antibody-based drugs worldwide. The company's pipeline includes 12 core products, among which two products are in Phase II multi-regional clinical trials and two products are in Phase I clinical trials. It focuses on developing drugs in the areas of oncology, autoimmune, inflammatory, metabolic, and other diseases. The company was founded in 2009 and is headquartered in Beijing, China. Beijing Biocytogen Co., Ltd. develops and prepares gene engineered animals to large-scale supply of animal models. It offers preclinical animal studies using gene humanized models, PDX models, and human immune system reconstruction models. The company's products include B-NDG mice, cre mouse models, cre rat models, B-p53 KO mice, B-ApoE KO mice, B-hIL6 mice, B-IL17-EGFP KI mice, B-TGFb1 cKO mice, genome- edited hESC, luciferase reported stable tumor cell lines, B-Pink1 KO rats, B-IL2rg KO rats, B-Cas9D10A cKI rats, B-ApoA4 KO rats, B-LDLR KO rats, B-Prkdc KO rats, B-Rag2 KO rats, B-tdTomato cKI rats, B-ApoE KO rats, B-hTnf mice, and B-hFcgrt (FcRn) mice. Beijing Biocytogen Co., Ltd. also develops antibody research and development platform and provides pharmacology services in the areas of tumor immunity, tumor and autoimmunity, and in vivo and in vitro pharmacology and pharmacology service platform. It also sells its products online. The company was founded in 2008 and is based in Beijing, China with additional locations in Beijing, Haimen, Jiangsu, Shanghai, China; Heidelberg, Germany; and Boston, the United States.
How the Company Makes MoneyBiocytogen Pharmaceuticals generates revenue primarily through the development and commercialization of antibody drugs. The company employs a revenue model that includes out-licensing its proprietary antibodies to pharmaceutical partners, collaborating on joint research projects, and engaging in contract research and development services. These partnerships and collaborations often involve upfront payments, milestone payments based on the achievement of clinical and regulatory goals, and royalties on sales of products developed using Biocytogen's technology. The company also benefits from strategic alliances that enhance its research capabilities and expand its market reach.

Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H Financial Statement Overview

Summary
The company has shown significant revenue growth and improved profitability with a positive net income and enhanced EBIT margins. However, the net profit margin remains low, and there is room for improvement in return on equity.
Income Statement
65
Positive
The company has shown significant revenue growth with a 36.8% increase from 2023 to 2024. Gross profit margin is strong at 77.7% for 2024, indicating effective cost management. However, the net profit margin is low at 3.4%, reflecting challenges in profitability despite positive net income in 2024. The EBIT margin improved significantly to 16.8% from a negative position in the previous year.
Balance Sheet
60
Neutral
The company's debt-to-equity ratio is 0.68, indicating a moderate level of leverage. The equity ratio is 34.5%, showing a stable financial structure. Return on equity is modest at 4.0%, suggesting room for improvement in generating returns on shareholders' equity.
Cash Flow
70
Positive
The free cash flow improved to 174.1 million from a negative position in the prior year, with a substantial free cash flow growth rate. The operating cash flow to net income ratio is 6.3, indicating strong cash generation relative to net income. However, stability in cash flow generation should be monitored.
BreakdownDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue980.45M716.91M533.88M354.56M253.54M
Gross Profit761.52M506.03M391.75M247.44M166.99M
EBITDA303.80M-97.87M-413.31M-378.12M-318.44M
Net Income33.54M-382.95M-602.16M-585.60M-542.97M
Balance Sheet
Total Assets2.42B2.45B2.80B2.30B2.33B
Cash, Cash Equivalents and Short-Term Investments381.18M434.04M611.27M566.45M950.04M
Total Debt570.28M544.11M415.28M538.35M463.80M
Total Liabilities1.58B1.66B1.65B1.05B868.28M
Stockholders Equity834.06M785.89M1.15B1.25B1.45B
Cash Flow
Free Cash Flow174.12M-203.26M-543.94M-564.45M-531.73M
Operating Cash Flow211.25M-76.65M-303.27M-365.78M-225.31M
Investing Cash Flow-137.12M-100.28M-153.74M-84.13M-188.18M
Financing Cash Flow-92.03M-37.82M587.20M219.44M868.44M

Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H Technical Analysis

Technical Analysis Sentiment
Positive
Last Price24.58
Price Trends
50DMA
21.44
Positive
100DMA
17.45
Positive
200DMA
12.48
Positive
Market Momentum
MACD
1.40
Negative
RSI
58.79
Neutral
STOCH
64.89
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:2315, the sentiment is Positive. The current price of 24.58 is above the 20-day moving average (MA) of 22.77, above the 50-day MA of 21.44, and above the 200-day MA of 12.48, indicating a bullish trend. The MACD of 1.40 indicates Negative momentum. The RSI at 58.79 is Neutral, neither overbought nor oversold. The STOCH value of 64.89 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HK:2315.

Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H Peers Comparison

Overall Rating
UnderperformOutperform
Sector (50)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
66
Neutral
HK$10.64B281.694.16%34.39%
57
Neutral
HK$18.57B-51.40%58.75%-1310.16%
55
Neutral
HK$19.13B-18.87%16.35%-49.63%
53
Neutral
HK$11.51B-13.97%-97.81%-117.20%
53
Neutral
HK$12.15B-55.68%-4.33%
50
Neutral
AU$2.60B3.64-58.14%2.69%36.37%13.78%
HK$10.20B116.504.95%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
HK:2315
Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H
24.58
18.37
295.81%
HK:1672
Ascletis Pharma, Inc.
11.91
11.03
1253.41%
HK:2157
Lepu Biopharma Co. Ltd. Class H
9.38
6.33
207.54%
HK:2162
Keymed Biosciences, Inc.
66.15
32.50
96.58%
HK:2171
CARsgen Therapeutics Holdings Ltd.
20.08
16.14
409.64%
HK:6955
Shandong Boan Biotechnology Company., Limited. Class H
17.08
8.13
90.84%

Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H Corporate Events

Biocytogen Pharmaceuticals Reports Strong Revenue Growth and Profit Turnaround in H1 2025
Aug 4, 2025

Biocytogen Pharmaceuticals announced preliminary financial data for the first half of 2025, showing a significant revenue increase of approximately 50.1% to 52.5% compared to the previous year, with expected revenues between RMB616.0 million and RMB626.0 million. The company also anticipates a turnaround from a loss to a net profit ranging from RMB42.7 million to RMB52.7 million, driven by strategic R&D investments and expansion in overseas markets, which have bolstered its competitive position and facilitated rapid growth in both domestic and international sectors.

Biocytogen Pharmaceuticals Initiates Share Repurchase and Award Scheme
Jun 13, 2025

Biocytogen Pharmaceuticals announced a voluntary share repurchase plan, approved at its 2024 AGM, to buy back up to 11,078,192 H Shares, representing 10% of its H Shares and 2.77% of its total issued share capital, using internal funds up to HK$50 million over the next 24 months. The repurchased shares may be held as Treasury Shares or used for employee share awards, with the company appointing Kastle Limited to manage the repurchase and CMB Wing Lung (Trustee) Limited to oversee the Share Award Scheme, all while adhering to regulatory requirements and market conditions.

Biocytogen Secures Japan Patent for RenMab Platform, Strengthening Global IP Strategy
Jun 5, 2025

Biocytogen Pharmaceuticals has secured a patent in Japan for its RenMab™ fully human antibody mouse platform, marking a significant milestone in its global intellectual property strategy. This achievement enhances the company’s competitive edge in the biotech industry, as the RenMice platform has already generated numerous licensing agreements and high-potential therapeutic candidates, underscoring its substantial commercial value and global recognition.

Biocytogen Pharmaceuticals Concludes Successful 2024 AGM with Strong Shareholder Support
May 28, 2025

Biocytogen Pharmaceuticals held its 2024 Annual General Meeting on May 28, 2025, combining a physical and virtual format. The meeting saw participation from shareholders representing 81.27% of the total voting shares. Key resolutions were voted on, with certain shareholders abstaining due to conflicts of interest, ensuring compliance with regulatory requirements. All resolutions were passed by poll, reflecting strong shareholder support and adherence to corporate governance standards.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Jul 31, 2025